GW starts cannabis trials in Canada

GW Pharmaceuticals (LSE:GWP) began double-blind Phase II studies of sub-lingual cannabis-extract spray in multiple sclerosis, spinal cord injury, and other forms of chronic pain. In the U.K. Phase III...